Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

@article{Ge2009GeneticVI,
  title={Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance},
  author={D. Ge and J. Fellay and A. Thompson and J. Simon and K. Shianna and T. Urban and E. Heinzen and P. Qiu and A. Bertelsen and A. Muir and M. Sulkowski and J. McHutchison and D. Goldstein},
  journal={Nature},
  year={2009},
  volume={461},
  pages={399-401}
}
  • D. Ge, J. Fellay, +10 authors D. Goldstein
  • Published 2009
  • Medicine, Biology
  • Nature
  • Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-α-2b (PegIFN-α-2b) or -α-2a (PegIFN-α-2a) combined with ribavirin (RBV), it is well known that many patients will not be cured by treatment, and that patients of European ancestry have a significantly higher probability of being cured than patients of African… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft… Expand
    ConditionsHepatitis C Recurrence After Liver Transplant
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    Objective: Pegulated Interferon α2 plus ribavirin is a treatment of choice in patients with chronic hepatitis C infection. This study was conducted to find out the frequency of… Expand
    ConditionsHepatitis C, Hepatitis C Relapse
    InterventionDrug

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 41 REFERENCES
    Gene expression and hepatitis C virus infection
    • 112
    • PDF